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Abstract 
Background and Significance:  Cases of Excited Delirium Syndrome have been increasing in 
association with the use of stimulants, and is a likely cause of sudden cardiac death in patients 
under simultaneous physical restraint  Our aim was to assess the effectiveness of ketamine 
compared to midazolam as a sedative through a pre-administration and post-administration 
data collection tool, using a modified Ramsay sedation scale, and secondarily identify factors 
associated with the need for airway support. 
Research Question: Is IV/IM ketamine administration to patients with an acute agitated 
delirium more effective at sedation than Midazolam alone for prehospital transport to an acute 
care facility? 
Methods: We conducted a prospective observational study of patients, 18 years or older, who 
received emergency medical assistance from paramedics over a 4-month period and received 
ketamine for sedation in the setting of an acute agitated delirium.  In order to establish a mode 
of comparison, we created an additional pre-survey to identify a subgroup of paramedics who 
had also previously administered midazolam for the purpose of sedation in an acutely agitated 
patient and asked them which medication they prefer.  Sedation was defined as a decrease in 
patient arousal that permits a safe transport and any necessary medical intervention. 
Results: N=55, median dose 400mg, effective sedation was achieved in 92.73% of patients.  
Airway compromise was noted in 8/55 patients (14.55%), and 3 required endotracheal 
intubation.  A potentially predictive factor associated with intubation was onset of action less 
than 2 minutes (p value = 0.065, trending toward significance).  On-scene evidence suggestive 
of concurrent use of CNS depressants as reported by paramedics was present in 49.09% of 
patients but was not predictive for time of sedation onset or airway compromise.  The level of 
agitation did not correlate with level of sedation after receiving ketamine or the need for 
airway support.  Eighty-two paramedics had previously given midazolam for sedation of an 
agitated patient and 53 (64.6%) felt that it was effective.  Sixty-two (89.86%) prefer to use 
ketamine over midazolam for sedation of the agitated patient.  
Conclusion: Ketamine is an effective sedative in 92.73% of adult patients presenting with 
agitated delirium; however, a rapid onset of sedation should make the provider suspicious for 
impending respiratory failure particularly if they required an additional dose. Additionally, 
prehospital providers found ketamine to be more effective at sedation and prefer it’s use over 
midazolam. 
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Introduction/Significance  
Excited Delirium Syndrome (ExDS) is described as a disorder characterized by hallucinations, 
aggressive and peculiar behaviors, a catecholaminergic surge and secondary risk for sudden 
cardiac death (Gerold, 2015).  A chronic disorder, Bell’s Mania, similar to ExDS in 
symptomatology was described by Luther Bell in 1849; other identifiers such as manic delirium, 
fulminating psychosis or exhaustive syndrome referred to this condition as well.  With the 
development of sedatives and antipsychotics the incidence declined greatly until 1980s.  During 
the 1980s to 2005, the use of stimulants such as cocaine and methamphetamines increased, as 
did the rates of “undetermined cause of death” in patients who were in custody and exhibited 
signs and symptoms of an acute agitated delirium.  It was concluded that patients in this state 
may be in danger of avoidable death.  Emergent medical treatment is required to prevent 
death, particularly in the setting of any kind of physical restraint.  The use of restraints was 
found in more than half of the patients who died during retrospective review of patients with 
“undetermined cause of death,” indicating a need for sedation that minimizes the use of 
physical restraint and sedates the patient chemically.  Sedation decreases the chances of the 
toxic catecholaminergic outpouring during altercations, usually with EMS providers or police 
who are trying to provide medical management, that is implicated as the cause of sudden 
cardiac death.  This disorder is recognized by The American College of Emergency Physicians 
(ACEP) and National Association of Medical Examiners (NAME), but has not yet been recognized 
by the American Medical Association (AMA) or American Psychiatric Association (APA), nor 
does it have its own code in the most recent ICD-10 or DSM V.  
Ketamine is an excellent choice for sedation and management of this patient population, 
especially in the field, from an armamentarium of pharmacologic agents (Peltoniemi et al., 
2016).  The mechanism of action of ketamine is noncompetitive antagonism specific to NMDA 
receptors preventing Ca2+ ion influx and activation of secondary messengers and release of 
glutamate as well as alternate activation by glycine and glutamate, an excitatory 
neurotransmitter.  Additionally, it is not active on opioid or GABA receptors making naloxone 
and flumazenil ineffective antidotes and respiratory depression unlikely.  The dosing protocol 
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supported by the Phoenix Fire Department (1-2 mg/kg slow IV push over 1 minute or 4mg/kg 
IM) very closely resembles the recommended dosing by Peltoniemi et al. (2016) of 0.5-1.0 
mg/kg IV bolus followed by maintenance infusion or repeated blousing or 2-4 mg/kg IM.  
However, the differences in the setting of administration can account for the minor differences 
of dosing particularly with ketamine’s large therapeutic index.  Although a majority of the 
patients in this study will not be truly suffering from ExDS, ketamine sedation and rapid 
management of the acutely agitated and violent patient will facilitate assessment and 
intervention for those who may be suffering from other emergencies including but not limited 
to hypoglycemia, hypoxia, overdoses of other drugs or poisons, infection or intracranial lesions 
or need safe transport to prevent undue harm to themselves or others.  It is our goal to assess 
the complications associated with its use in the prehospital setting as well as to predict the 
likelihood and associated risk factors for respiratory failure to assist providers in their 
management in the future. 
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Materials and Methods 
In this study, we evaluated whether or not Phoenix Fire Department paramedics assessments 
indicate that IV/IM ketamine administration to patients with Excited Delirium Syndrome is 
more effective at sedation than Midazolam alone for prehospital transport to an acute care 
facility.  Additionally, we wanted to attempt to predict intubation and potentially identify risk 
factors that could be recognized early on to clue the paramedic into potential respiratory 
failure.  A validated data collection tool (Figure 1) was used to assess the sedative effect of each 
independent ketamine administration and a comparison to midazolam (Figure 2) was 
established by a pre-survey which was filled out one time by each paramedic.  
A data collection tool was asked to be filled out after every patient encounter by each 
paramedic to represent that single patients’ and paramedics’ ketamine experience.  Seventy-
five data collection tools were turned in, but 20 of them were incomplete or filled out 
incorrectly.  Therefore, we were able to complete the data interpretation on a sample size of 
n=55 patients.  This was considered adequate after a power analysis was completed 
demonstrating a need for a minimum sample size of 12.   
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Figure 1: Validated Ketamine Data Collection Tool 
Date: 
Before Ketamine Administration 
How would you rate their level of agitation on a scale of 1-6? (circle one) 
• 1 – minimal (verbal de-escalation effective) 
• 2 - mild (oriented, uncooperative with exam) 
• 3 – confused (unable to follow commands) 
• 4 -  moderate (combative) 
• 5 -  severe (danger to self or others) 
• 6 -  extreme (PD escort) 
Were you able to obtain vital signs? Yes No 
Did this patient require physical restraint?  Yes No 
What dose and what route did you administer the ketamine? 
(circle one)  IV  /   IM _____mg 
Where was the IM injection site? (circle one) 
Deltoid 
Gluteus/ 
Thigh 
After Ketamine Administration 
Did the vital signs (re)assessments trend toward improvement? 
(based on vital signs that would be classified as “normal”) Yes No 
How long until you were able to initiate the next steps in 
management of the patient after ketamine administration? 
(circle one) 
2     4     6    8    10 minutes 
How would you rate their level of sedation on a scale of 1-6 after administering ketamine? 
• 1 – asleep:  No response 
• 2 – asleep:  Sluggish response  
• 3 – asleep:  Brisk response  
• 4 – awake:  Responds to commands 
• 5 – awake:  Cooperative and oriented 
• 6 – awake:  Anxious/agitated  
Did the patient require secondary intervention related to 
complications of their state of agitated delirium? (ACLS, injury 
to self) 
Yes No 
Did you give additional ketamine? 
(Report route and dose) 
Yes No 
 5 
 
  
Did the patient require airway or ventilatory support at any 
time after ketamine administration or before you left the 
receiving facility? 
If yes, circle interventions used. 
o BVM 
o LMA 
o OPA 
o ETT 
Yes No 
Did the patient require fluid resuscitation? Yes No 
Were there any indications that the patient may have been 
under the influence of other CNS depressants (alcohol, opioids, 
benzodiazepines, barbiturates, etc.) 
Yes No 
Did the patient have any of the listed adverse reactions of 
ketamine? 
If yes, circle all that apply.   
o Laryngospasm 
o Hypersalivation 
o Emergence reactions (vivid dreams, hallucinations, or 
delirium) 
o Respiratory depression?  
Yes No 
In the past, have you ever administered Midazolam for the 
purpose of sedating a patient who was showing signs or 
symptoms of an acute or agitated delirium? (If yes, proceed to 
next question) 
Yes No 
If yes, which medication do you think was more effective at 
sedation to allow safe intervention and transport: Midazolam or 
Ketamine? 
Midazolam Ketamine 
Which would you prefer to give if you had the option of both? Midazolam Ketamine 
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Figure 2: Midazolam Comparison Pre-survey 
Pre-survey Questions Yes No 
1. Have you ever administered Midazolam to a patient with 
acute agitated delirium?   
2. Did you feel it was effective at sedating your patient to 
allow medical intervention?   
3. Have you ever administered Ketamine for acute agitated 
delirium?   
4. Did you feel it was effective at sedating your patient to 
allow medical intervention?   
5. Which medication did you think was most effective at 
sedation? Ketamine Midazolam 
6. Which medication do you prefer to use? Ketamine Midazolam 
7. Do you feel confident in your skills/knowledge when using 
ketamine as a sedative?   
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A prospective analysis was utilized to assess EMS providers’ experiences with Ketamine as the 
primary agent utilized in managing violent agitated and combative patients, who may also 
display specific signs and symptoms of ExDS.  Sedation was defined as a decrease in patient 
arousal that permitted a safe environment and allowed the paramedic to assess the medical 
status of the patient such that at least vital signs and ECG tracing could be obtained during 
transport to an acute care facility. 
The patients in the study received IV/IM ketamine administered by a paramedic, as indicated by 
the protocol written by the Medical Director with the Phoenix Fire Department.  The 
paramedics, during every ketamine administration, were expected to follow proper 
documentation protocol with a minimum of, but not limited to:  
• Scene assessment upon arrival and chief complaint 
• Vital signs (2 sets) 
o heart rate, respiratory rate, blood pressure, temperature, pulse oximetry 
• Finger stick blood glucose level 
• Interventions pertaining to airway, breathing and circulation 
o Medications 
 Intravenous fluids, sedative medications, supplemental oxygen, etc. 
o Procedures 
 Positive pressure ventilation, intravenous access, cooling, etc. 
• If restraints were used: 
o Reason 
o Position 
o Status of circulation distal to restraints, assessed every 10 minutes 
o Patient status at time of transfer of care 
o Total time patient was restrained 
• Any obtainable past medical history, social history, allergies, medications, 
alcohol/tobacco/illicit drug use 
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After leaving the facility, the paramedic was able to participate in the data collection by filling 
out the survey at this time. This questionnaire was available to the administering paramedic at 
the fire station, in the fire engine and in the ambulance as well as at any continuing education 
classes for timely and convenient completion.  Collection was mediated through interoffice mail 
and collected monthly as well as turned in after any continuing education classes.   
The standardized data collection questionnaire assessed their individual experience with the 
use of ketamine as an effective agent to safely manage the violent, agitated or combative 
patient during assessment and transport.  The data collection tool was validated prior to 
institution by giving it to the paramedics during continuing education classes taught by the 
Medical Director.  This ensured it was interpreted uniformly and consistently across various 
paramedics with varying previous experiences prior to implementation in the study.  The tool 
was adjusted until this focus was obtained through changes in the length, verbiage or flow of 
the questionnaire. 
  
 9 
Statistical Analysis 
The primary outcome for this analysis is whether the patients were responsive to stimuli versus 
those who were not after ketamine administration.  Survey characteristics were assessed using 
means, standard deviations for continuous variables and frequencies, proportions for 
categorical variables.  Univariate logistic regression was used to assess whether the survey 
characteristics were independently associated with being unresponsive post ketamine 
administration.  All covariates with p<0.20 were entered into a second multivariate model to 
assess whether the selected covariates best predictive of post-ketamine unresponsiveness.  The 
same procedure of univariate and multivariate logistic regression was used for the secondary 
outcomes of pre-ketamine agitation, and onset of Medication.  All p-values were two-sided and 
p<0.05 was considered statistically significant. All data analysis were conducted using STATA 
version 14 (College Station, TX).   
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Results 
A total of 152 presurveys were collected, in which 51 (33.55%) were incomplete or filled out 
incorrectly.  Of note, within these surveys, only 87/101 (86.14%) paramedics had administered 
both ketamine and midazolam during their career, allowing their response to be utilized as a 
subject within the comparison population.  Paramedics were asked to only fill out this survey 
once. 
Data was collected from November 2016 to March 2017 and a total of 55 patients were 
enrolled in the study via survey completion by the paramedic who administered the ketamine.  
It is unknown how many patients actually received ketamine during this time frame because 
participation in the study was optional for the paramedic.  Agitation was graded on a Likert 
scale from 1-6; 25/55 (45.45%) patients were deemed to have severe agitation requiring a 
police escort to facilitate care and transport of the patient to the hospital.  Twenty-one 
(38.18%) were described as a danger to themselves or others, 8 (14.55%) were described as 
combative and 1 (1.82%) was described as being unable to follow commands.  The paramedics 
were able to obtain vitals on 39/55 (70.91%) of the patients and the ketamine was 
administered intramuscularly 94.55% (52/55) of the time.  Fifty patients received the 
intramuscular injection in the deltoid, and five patients received the dose in the vastus lateralis.   
Dosing was repeated in 8/55 (14.55%) patients, however the repeat dose and route was not 
collected. 
Most administrations resulted in an onset of sedation within two minutes (26/55; 47.27%), but 
34.55% (19/55) had onset within four minutes, 16.36% (9/55) had onset within six minutes, 0 
reports of eight minutes and 1.82% (1/55) reported 10 minutes.  Upon reassessment of the 
patients, 84.55% of patients demonstrated an improvement in their vital signs after sedation 
and on a second Likert scale, which was a modified take on the Richmond Agitation-Sedation.  
When classified as being asleep or awake, 85.45% were described as “asleep” and further 
categorized according to their response to stimulation: None (21/55, 38.18%), sluggish (21/55, 
38.18%), brisk (5/55, 9.09%).  Eight patients were classified as awake, and further described as 
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responding to commands (3/55, 5.45%, cooperative and oriented (1/55, 1.82%) or still 
anxious/agitated (4/55, 7.27%).   
Spearman’s rho (-0.0035) was performed to determine if there was a relationship between the 
level of agitation and the need for additional ketamine and found that they were not associated 
with one another.  Additionally, the agitation scale in the data collection tool was not predictive 
of needing additional ketamine in a two-sample Wilcox rank-sum test (z = 0.9793), though 
repeat dosing did increase the likelihood for effect on the need for ventilatory support (Fisher’s 
exact = 0.587).  One thing to note however, is that the patient was 3.6 more likely to be 
unresponsive after additional dosing, and this was associated with two-fold increase in the 
need for ventilatory support.  Lastly, their level of agitation was not associated with the patient 
needing secondary intervention after sedation was achieved (Spearman’s rho = -0.1084, 
t=0.4307).  This was also repeated with a two-sample Wilcoxon rank sum test without identified 
relationship (z = 0.4255). 
The onset of sedation after ketamine administration was not associated with the patient’s pre- 
or post-sedation scales.  It was ultimately effective in 92.73% of patients despite taking up to 10 
minutes to be able to provide the next steps in care.  The odds ratio for pre-ketamine 
administration and association with onset of action was 0.38 (0.12, 1.1 with a 95%CI, p=0.08), 
and the post-sedation odds ratio was even more valuable with a statistically significant result of 
0.27 (0.08, 0.85) with a 95% CI, p=0.02.  Administration of additional ketamine did not effect 
the onset of action (OR 0.31, p=0.18).  When using Spearman’s rho (0.2503) to assess the 
relationship between the onset of action of ketamine and the need for airway support, the 
correlation was trending toward significance with a p-value of 0.0653; however, this was not 
supported by the odd’s ratio of 0.24 (0.05, 1.4; 95% CI, p=0.10).  
When airway ventilation was compared against various exposures (table 3), secondary 
intervention occurred in all of these patients with an OR 20.5 (3.3, 125.9, 95% CI, p=0.001).  
However, it is unknown if the secondary intervention was limited to just the airway support (i.e. 
OPA, LMA or ETT) or if there were other interventions that the data collection tool was not able 
to capture.   
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In the multivariate analysis (Table 4), most of the statistically significant data did not persist 
after the adjusted odds ratio. Specifically, whether or not onset of sedation after ketamine 
administration was correlated with the need for advanced airway support AOR 0.34(0.04, 2.9; 
p=0.32 and area under the curve 0.80). The pre-sedation agitation scale continued to have no 
relationship with the onset of sedation or final post-sedation scale with the follow AOR, 
respectively, AOR 0.31 (0.09, 1.04, p=0.05) and AOR 0.28 (0.08, 1.01, p=0.05) and area under 
the curve equal to 0.76). 
When examining the data qualitatively as two independent variables, ketamine was effective at 
sedation and positively influenced patient care based on the data collection questionnaire 
results (Table 1).  Ketamine expedited the time frame for intervention in 81.82% (OR 3.7; 95% 
CI, p=0.02) of patients by allowing initiation of care within four minutes.  Additionally, ketamine 
was unlikely to be associated with need for ventilatory support or repeat dosing, and 
respectively, had an odds ratio of 0.30 (0.06, 1.4 with a 95% CI, p=0.13) and 0.19 (0.02, 1.6, with 
a 95% CI, p=0.13); though these results were not statistically significant. 
Secondary interventions related to complications of their agitation were reported in 8/55 
(14.55%) of patients but were not defined by the data collection tool.  Additionally, in order to 
protect private health information, there was no way to follow-up on any of the individual 
patients or said complications.  We did specifically inquire about the need for needed airway 
support in order to try to predict the likelihood for intubation with ketamine.  Eight of the 55 
patients (14.55%) were reported to need airway support, 3/8 (37.5%) of which required 
endotracheal intubation, 4/8 (50%) had a laryngeal mask airway placed and 1/8 (12.5%) was 
supported with an oral pharyngeal airway.  Additionally, one person had hypotension requiring 
fluid resuscitation. 
The paramedics were also asked if there was any indication that they patient make have been 
under the influence of any central nervous system depressants, such as alcohol, opioids, 
benzodiazepines or barbiturates.  Twenty-seven of the 55 (49.09%) patients were reported as 
yes, and 28/55 (51.9%) did not have any indication of other potentially depressant intoxicants.  
A report was adverse reactions was recorded as a binary yes (5/55, 9.09%) or no (50/55, 
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90.91%), with the option to describe the reaction or select one of the common adverse 
reactions known to ketamine.  Zero reports of laryngospasm occurred, 1/5 (16.67%) had 
hypersalivation, 1/5 (16.67%) had an emergence reaction, and 3/5 had respiratory depression 
(60%).  One patient was described as having one of the above-mentioned adverse effects under 
the description “other” after the paramedic received hospital follow-up, but it is unknown 
which adverse reaction occurred. 
At the end of the survey, the paramedics were asked to report whether or not they had given 
midazolam for the same purpose; 39/55 (70.91%) had reported yes, and 16/55 (29.09%) 
reported no.  Based on those who answered yes, 37/39 (94.87%) reported that ketamine was 
more effective at sedation to allow safe medical intervention and transport and would also 
prefer to use ketamine over midazolam in this patient population. 
  
 14 
Table 1: Sedation post ketamine administration 
     
Survey Characteristics Response to Stimuli 
N=34 
Unresponsive  
N=21 
OR (95% CI) P-value 
     
Pre-Ketamine Agitation (yes, %) 16 (47.1) 9 (42.8) 1.18 (0.39, 3.5) 0.76 
     
Were you able to obtain vital 
signs? (yes, %) 
11 (32.4) 5 (23.8) 1.53 (0.44, 5.2) 0.49 
     
Did this patient require physical 
restraint? (yes, %) 
32 (94.1) 21 (100.0) N/A  
     
Route Administration (IM, %) 31 (31.2) 21 (100.0) N/A  
     
After you administered 
ketamine, approximately how 
long until you were able to 
initiate the next steps in 
management of the patient? 
 (>4 min, %) 
22 (64.7) 7 (33.3) 3.7 (1.2, 11.6) 0.02 
     
Did the patient require 
secondary intervention related 
to complications of their state of 
agitated delirium? (yes, %) 
8 (23.5) 4 (19.1) 1.31 (0.34, 5.0) 0.69 
     
Did you give additional 
ketamine? (yes, %) 
27 (79.4) 20 (95.2) 0.19 (0.02, 1.6) 0.13 
     
Did the patient require airway or 
ventilatory support at any time 
after ketamine administration or 
before you left the receiving 
facility?  
(yes, %) 
3 (8.8 ) 5 (23.8) 0.30 (0.06, 1.4) 0.13 
     
Did the patient require fluid 
resuscitation? (yes, %) 
0 (0.0) 1 (4.7) N/A  
     
Were there any indications that 
the patient may have been 
under the influence of other CNS 
depressants? (yes, %) 
16 (47.1) 11 (52.4) 0.80 (0.27, 2.4) 0.70 
     
Did the patient have an adverse 
reaction to ketamine? (yes, %) 
5 (14.7) 5 (23.8) 0.55 (0.13, 2.2) 0.39 
     
In the past, have you ever 
administered Midazolam for the 
purpose of sedating a patient 
who was showing signs or 
symptoms of an acute or 
agitated delirium?  
(yes, %) 
10 (29.4) 6 (28.5) 1.04 (0.31, 3.5) 0.94 
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Table 2: Onset of action 
     
Survey Characteristics < 4min Onset 
N=26 
>4 min Onset 
N=29 OR (95% CI) P-value 
     
Pre-Ketamine Agitation (yes, %) 15 (57.7) 10 (34.5) 0.38 (0.12, 1.1) 0.08 
     
Were you able to obtain vital signs? 
(yes, %) 9 (34.6) 7 (24.1) 0.60 (0.18, 1.9) 0.39 
     
Did this patient require physical 
restraint? (yes, %) 24 (92.3) 29 (100.0) N/A  
     
What route did you administer the 
ketamine? (IM, %) 25 (96.2) 27 (93.1) 0.54 (0.05, 6.3) 0.62 
     
How would you rate their level of 
sedation? (No Response, %) 14 (53.8) 7 (24.1) 0.27 (0.08, 0.85) 0.02 
     
Did the patient require secondary 
intervention related to complications 
of their state of agitated delirium? 
(yes, %) 
7 (26.9) 5 (17.2) 0.56 (0.15, 2.1) 0.38 
     
Did you give additional ketamine? 
(yes, %) 24 (92.3) 23 (79.3) 0.31 (0.06, 1.7) 0.18 
     
Did the patient require airway or 
ventilatory support at any time after 
ketamine administration or before 
you left the receiving facility? (yes, %) 
6 (23.1) 2 (6.9) 0.24 (0.05, 1.4) 0.10 
     
Did the patient require fluid 
resuscitation? (yes, %) 1 (3.9) 0 (0.0) N/A  
     
Were there any indications that the 
patient may have been under the 
influence of other CNS depressants? 
(yes, %) 
11 (42.3) 16 (55.2) 1.67 (0.57, 4.9) 0.34 
     
Did the patient have an adverse 
reaction to ketamine? (yes, %) 6 (23.1) 4 (13.8) 0.53 (0.13, 2.2) 0.37 
     
In the past, have you ever 
administered Midazolam for the 
purpose of sedating a patient who 
was showing signs or symptoms of an 
acute or agitated delirium? 
(yes, %) 
9 (34.6) 7 (24.1) 0.60 (0.18, 1.9) 0.39 
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Table 3: Airway Ventilation 
     
Survey Characteristics No 
N=47 
Yes 
N=8 OR (95% CI) P-value 
     
Pre-Ketamine Agitation (yes, %) 21 (44.7) 4 (50.0) 1.23 (0.27, 5.6) 0.78 
     
Were you able to obtain vital 
signs? (yes, %) 13 (27.7) 3 (37.5) 1.56 (0.32, 7.5) 0.53 
     
Did this patient require physical 
restraint? (yes, %) 45 (95.7) 8 (100.0) N/A  
     
What route did you administer 
the ketamine? (IM, %) 44 (93.6) 8 (100.0) N/A  
     
How would you rate their level of 
sedation? (No Response, %) 16 (34.0) 5 (62.5) 3.2 (0.68, 15.3) 0.13 
     
Did the patient require 
secondary intervention related to 
complications of their state of 
agitated delirium? (yes, %) 
6 (12.8) 6 (75.0) 20.5 (3.3, 125.9) 0.001 
     
Did you give additional 
ketamine? (yes, %) 39 (82.9) 8 (100.0) N/A  
     
After you administered 
ketamine, approximately how 
long until you were able to 
initiate the next steps in 
management of the patient?  
(>4 min, %) 
27 (57.5) 2 (25.0) 0.24 (0.04, 1.4) 0.10 
     
Did the patient require fluid 
resuscitation? (yes, %) 0 (0.0) 1 (12.5) N/A  
     
Were there any indications that 
the patient may have been under 
the influence of other CNS 
depressants? (yes, %) 
24 (51.1) 3 (37.5) 0.57 (0.12, 2.3) 0.48 
     
Did the patient have an adverse 
reaction to ketamine? (yes, %) 2 (4.3) 8 (100.0) N/A  
     
In the past, have you ever 
administered Midazolam for the 
purpose of sedating a patient 
who was showing signs or 
symptoms of an acute or agitated 
delirium? 
(yes, %) 
13 (27.7) 3 (37.5) 1.56 (0.32, 7.5) 0.57 
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Table 4: Multivariate analysis with Adjusted Odds Ratio 
    
Predictors    
 AOR (95% CI) P-value Area Under the Curve 
    
Sedation Rate   0.72 
    
After you administered ketamine, 
approximately how long until you 
were able to initiate the next steps in 
management of the patient?  
0.33 (0.10, 1.1) 0.07  
    
Did you give additional ketamine? 3.67 (0.39, 34.4) 0.25  
    
Did the patient require airway or 
ventilatory support at any time after 
ketamine administration or before 
you left the receiving facility? 
2.04 (0.39, 10.5) 0.39  
    
Onset of Medication   0.76 
    
Pre-Ketamine Agitation 0.31 (0.09, 1.04) 0.05  
    
How would you rate their level of 
sedation? 0.28 (0.08, 1.01) 0.05  
    
Did you give additional ketamine? 0.46 (0.07, 2.8) 0.40  
    
Did the patient require airway or 
ventilatory support at any time after 
ketamine administration or before 
you left the receiving facility? 
0.33 (0.05, 2.1) 0.24  
    
Airway Ventilation   0.80 
    
How would you rate their level of 
sedation? 7.55 (0.66, 85.7) 0.10  
    
Did the patient require secondary 
intervention related to complications 
of their state of agitated delirium? 
42.4 (3.6, 488.9) 0.003  
    
After you administered ketamine, 
approximately how long until you 
were able to initiate the next steps in 
management of the patient?  
0.34 (0.04, 2.9) 0.32  
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Discussion 
As expected, ketamine was well received by the paramedic population and preferred over 
midazolam in 89.86% of paramedics as an agent that was effective at sedation for transport of 
patients with concern for excited delirium syndrome.  The questions in the data collection tool 
were analyzed independently of each other for any relationships that existed the individual 
questions.  Only one positive association was found and is also trending toward significance; 
when the onset of sedation was examined in the context of the patients who required 
ventilatory support, it was found that an onset of less than 2 minutes may predict risk for 
respiratory failure (p=0.653).  However, and unexpectedly, the onset of action did not 
demonstrate a relationship with paramedic scene assessment and clinical gestalt on whether or 
not the patient was under the influence of other central nervous system depressants.  There 
was also no connection between patients in whom the paramedic suspected or saw physical 
evidence of other depressant medications and the risk for needing ventilatory support (Fisher’s 
exact 0.705) or if there was a reported adverse reaction (Fisher’s exact = 0.729) in the agitated 
patient who received ketamine.   In the multivariate analysis, patient who received an 
additional dose of ketamine were 3.6x more likely to be unresponsive, of which these patients 
had a 2-fold increased risk for respiratory failure.  Repeat dosing was not directly related to 
need to for ventilatory though, however.  These important negative findings are in line with our 
original hypothesis and support the use of ketamine as a prehospital medication for agitated 
delirium, but with continued caution and need for more education by the provider.   
Our study and data are similar in comparison to what already exists on prehospital ketamine in 
the literature.  For example, in the article, “Prehospital Use of IM Ketamine for Sedation of 
Violent and Agitated Patients,” (Scheppke et al., 2014) they had a similar sample size, n=52; 
however, half of the patients received midazolam IV to “prevent” emergence reactions 
associated with ketamine, such as hallucinations.  Additionally, the study demonstrated that 
respiratory depression was an untoward outcome in 6% of the patients, all of which involved 
subsequent midazolam administration. In our study, only one patient was noted to have an 
emergence reaction out of 55 subjects, making it unlikely that the number needed to treat is 
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greater than the number needed to harm by prophylactic midazolam.  Their study was also an 
entirely retrospective chart review without consideration of input from the paramedics who 
administered the medications or their assessment of the patient after the initial dose of 
ketamine.  It is questionable whether the patients truly needed additional sedation by 
midazolam or if ketamine by itself was sufficient for transport and initiation of emergency 
medical management.  The study did not discuss any untoward outcomes related to ketamine 
administration independent of midazolam, but this sample size is even smaller, n=26. Out larger 
sample size did catch an increased incidence of airway compromise (8/55 patients), potentially 
because of the increased number of subjects in our study.   
Their limitations were similar to the limitation in our study, such as the sample size, and follow-
up of outcomes upon arrival to the emergency department with or without untoward effects 
from the medications administered.  Additionally, no statistical power methods were applied to 
their data sets to provide confidence intervals for their analysis. In the article, Ketamine for pre-
hospital control of agitated delirious patients: Promising but not yet ready for prime time by 
Schultz (2014), a critical examination was performed of the study by Scheppke et al. (2014) and 
listed similar reservations related to the methods used and an increased need for more 
research to establish if ketamine is truly a safe and effective treatment for this vulnerable 
patient population.   
Another study, “The Use of Prehospital Ketamine for Control of Agitation in a Metropolitan 
Firefighter-based EMS System,” by Keseg et al. (2015) evaluated the use of ketamine as a 
sedative for combative patients administered by paramedics.  The efficacy and safety of the 
drug in this setting was evaluated with retrospective chart review as well on an even smaller 
sample size, n=35, that had more specific parameters than the study by Scheppke (2014), but 
was of little contribution due to the binary questionnaire utilized to evaluate “improve[ment].”  
Additionally, an EMS liaison between the hospitals who received these patients and the EMS 
system were able to contribute more data to further investigate patient outcomes upon arrival 
to the emergency department.  The limitation of this study includes the lack of identification of 
qualitative and quantitative data that would indicate how the patient “improve[d].”  We believe 
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our study is somewhat similar to this in the sense that it utilized a survey, however the 
prospective data that we obtained and larger sample size make the results of a more robust 
contribution to the current literature. 
Lastly, the study “Ketamine as Rescue Treatment for Difficult-to-Sedate Severe Acute 
Behavioral Disturbance in the Emergency Department,” by Isbister et al. (2015) examined 
Ketamine as a rescue agent in patients with violent and agitated delirium after treatment 
failure. The initial pharmacologic treatment was Droperidol, a typical antipsychotic, and in a 
small number of cases various benzodiazepines were utilized.  In 41% of the patients, the 
behavior was severe enough and required police assistance to protect emergency department 
and EMS staff from the patient as well as the patient from harming themselves.  The ketamine 
was successful at sedation in all cases; however, repeat dosing was required in patients who 
received an initial dose less than 200mg IM. Unfortuantely, do to variability in the answers to 
the dosing question, we were not able to further substantiate this as the dosing was 
inconsistently reported between total dose and mg/kg.  This study by Isbister et al. 
recommends dosing greater than 200mg with a range of 4-6mg/kg.  The only adverse outcome 
in this study was vomiting in two patients and a pulse oximetry of 90% in one patient who 
responded immediately with supplemental oxygen.  All protective airway reflexes are 
maintained with ketamine and airway compromise was not reported in any cases post-
ketamine administration.  The fact that we had 8 episodes of airway compromise on a lower 
dosing regimen (1-2mg/kg IV or 5mg/kg IM), call the safety profile into question more so than 
may be first thought after reading their article. 
The gap in the literature failed to integrate the unique aspect of whether or not the paramedic 
who administered the ketamine observed that the patient did “improve” based on specific and 
measurable variables that are routinely recorded on the EMS run sheet by an educated 
paramedic’s assessment.  Additionally, an evaluation of a percentage of patients, with or 
without untoward affects, who were transferred was not thoroughly conducted.  Due to the 
fact that there has been an increasing incidence of “undetermined cause of death” in patients 
who have been restrained physically while in-custody and that the diagnosis of Excited Delirium 
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Syndrome is one of exclusion during a port mortem assessment, more efforts need to be aimed 
at reducing the likelihood in patients who present with signs and symptoms of Excited Delirium 
Syndrome from avoidable morbidity and possibly death (Gerold, 2015).  Furthermore, 
additional research and evidence is needed to further define ketamine as a first line agent in 
the prehospital setting to safely sedate and transport other patient populations (elderly, post-
traumatic brain injury, among many others) with agitated and violent behavior who may not 
have ExDS in the differential diagnosis, but do need urgent sedation or medical management to 
mitigate other suboptimal or adverse outcomes prior to arrival at the facility assuming care.  
Our data does provide more support for the use and safety profile of ketamine; however, with 
the above-mentioned limitations that were discussed we don’t think that with certainty it can 
be declared to be of minimal risk and that the administering provider should remain vigilant for 
complications.  
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Future Directions 
A larger sample size needs to be assessed preferably in a prospective fashion with the ability to 
follow-up on patients after hospital disposition has been determined.  It is curious how many of 
the patients who receive ketamine are truly suffering from an excited delirium as well as how 
many may have an untoward reaction after care has been transferred from the paramedics.  It 
would also be beneficial to know what the final diagnosis of a patient was who may have 
appeared to have an excited delirium syndrome and if ketamine is an agent that would be 
beneficial in more populations. 
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Conclusion 
 Ketamine is an effective sedative in 92.73% of adult patients presenting with agitated delirium; 
however, a rapid onset of sedation should make the provider suspicious for impending 
respiratory failure. Additionally, prehospital providers found ketamine to be more effective at 
sedation and 89.86% prefer it’s use over midazolam.  More research needs to be done to collect 
to support whether or not ketamine has an increased risk for complications during sedation, 
specifically airway compromise and the ability to predict who may need advanced airway 
support and if onset of action truly predicts impending respiratory failure. 
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